The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias

• Published in: Clinical pharmacology and therapeutics Vol. 43; no. 5; p. 499
• Main Authors: Wang, T, Siddoway, L A, Thompson, K A, Conard, G J, Bergstrand, R H, Kvam, D, Roden, D M, Woosley, R L
• Format: Journal Article
• Language: English
• Published: United States 01.05.1988
• Subjects: Adult; Aged; Arrhythmias, Cardiac - drug therapy; Female; Flecainide - administration & dosage; Flecainide - pharmacokinetics; Humans; Infusions, Intravenous; Male; Middle Aged
• ISSN: 0009-9236
• DOI: 10.1038/clpt.1988.65

A two-part pharmacokinetic approach was used to prospectively develop and test intravenous flecainide infusion regimens for the acute therapy for ventricular arrhythmias. Initially, each of nine known responders to oral flecainide was given a rapid flecainide infusion to characterize pharmacokinetic parameters and determine the minimum effective concentration for each patient. These data were used to calculate individually appropriate three-stage flecainide infusions of predetermined durations in eight patients. The three-stage infusions (0.15 +/- 0.02 mg flecainide acetate/kg/min for 5 minutes, 0.046 +/- 0.004 mg/kg/min for 60 minutes, and 0.31 +/- 0.05 mg/kg/hr for 5 to 47 hours; mean +/- SE) resulted in 95% +/- 0.1% suppression of ventricular ectopic depolarizations. Based on these results, six additional patients received a uniform infusion regimen (0.1 mg/kg/min for 5 minutes, 0.025 mg/kg/min for 2 hours, and 0.25 mg/kg/hr for 46 hours). Supplemental doses of 0.25 mg/kg were given (four doses per patient). With this protocol, ventricular ectopic depolarizations were 82.6% +/- 8.5% suppressed. Measured plasma flecainide concentrations were not significantly different from those predicted by pharmacokinetic models. A prompt and sustained antiarrhythmic effect was obtained with an intravenous regimen of flecainide determined by a prospective pharmacokinetic approach. However, the dosages developed in this study may have to be modified for patients with impaired cardiac or renal function.